



## Recent Advancements in Nanobiotechnology and Immunotherapy for the Treatment of Solid Tumors

Guest Editors:

### Dr. Francesco Mainini

Nanomedicine Laboratory,  
Department of Biomedical and  
Clinical Sciences "L. Sacco",  
University of Milan, via G.B.  
Grassi, 74 20157 Milan, Italy

### Dr. Ovidio Catanzano

National Research Council -  
Institute for Polymers,  
Composites and Biomaterials  
(IPCB-CNR), via Campi Flegrei 34,  
80078 Pozzuoli, Italy

Deadline for manuscript  
submissions:

**closed (20 August 2023)**

### Message from the Guest Editors

Dear Colleagues,

Onco-immunotherapies, such as immune checkpoint blockade inhibitors and adoptive cell therapies, are revolutionizing the field of cancer therapy due to their ability to induce strong anti-tumor immune responses. The use of nanoparticle-based delivery systems (NPs) to improve conventional onco-immunotherapies is gaining traction due largely to the versatility of this approach.

We are inviting the submission of high-quality research papers and reviews exploring the synergistic combinations between nanotherapeutics and immunomodulatory molecules for the treatment of solid tumors. We expect to receive contributions from different areas of multidisciplinary research, including (but not restricted to): innovative immunomodulatory nanomaterial design, NP surface functionalization and characterization, the relationship between the physicochemical properties of NPs and their immunomodulation properties, and potential new therapeutic applications in solid tumor treatment. This Special Issue aims to make a significant collective contribution to this field of study.

We look forward to receiving your contributions.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:**— free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

## Contact Us

---

*Pharmaceutics*  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
[@MDPIpharma](https://twitter.com/MDPIpharma)